Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas
Status:
Completed
Trial end date:
2018-02-17
Target enrollment:
Participant gender:
Summary
This is an open-label, single arm, multi-center, Phase II trial to evaluate the progression
free survival in patients with metastatic adenocarcinoma of the pancreas treated with a
hedgehog inhibitor (GDC-0449) in combination with chemotherapy (gemcitabine and
nab-Paclitaxel).
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators:
Celgene Corporation Genentech, Inc. Stand Up To Cancer